{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T12:59:27Z","timestamp":1782824367607,"version":"3.54.5"},"reference-count":10,"publisher":"American Society of Hematology","issue":"3","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,1,16]]},"DOI":"10.1182\/blood.2024027065","type":"journal-article","created":{"date-parts":[[2025,1,16]],"date-time":"2025-01-16T16:30:33Z","timestamp":1737045033000},"page":"253-255","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":7,"title":["Is it time to screen for multiple myeloma?"],"prefix":"10.1182","volume":"145","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7361-3092","authenticated-orcid":false,"given":"Irene M.","family":"Ghobrial","sequence":"first","affiliation":[{"name":"Dana-Farber Cancer Institute"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Floris","family":"Chabrun","sequence":"additional","affiliation":[{"name":"Dana-Farber Cancer Institute"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"3","key":"2025011616302733800_bib1","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1182\/blood.2024025415","article-title":"Comparison of progression risk of monoclonal gammopathy of undetermined significance by method of detection","volume":"145","author":"Visram","year":"2025","journal-title":"Blood"},{"issue":"22","key":"2025011616302733800_bib2","doi-asserted-by":"crossref","first-page":"5412","DOI":"10.1182\/blood-2008-12-194241","article-title":"Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study","volume":"113","author":"Landgren","year":"2009","journal-title":"Blood"},{"issue":"6","key":"2025011616302733800_bib3","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1038\/leu.2010.60","article-title":"Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management","volume":"24","author":"Kyle","year":"2010","journal-title":"Leukemia"},{"issue":"13","key":"2025011616302733800_bib4","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1056\/NEJMoa054494","article-title":"Prevalence of monoclonal gammopathy of undetermined significance","volume":"354","author":"Kyle","year":"2006","journal-title":"N\u00a0Engl J Med"},{"issue":"10","key":"2025011616302733800_bib5","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1038\/s41408-020-00366-3","article-title":"International Myeloma Working Group risk stratification model for smoldering multiple myeloma (SMM)","volume":"10","author":"Mateos","year":"2020  16","journal-title":"Blood Cancer J"},{"issue":"7","key":"2025011616302733800_bib6","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1038\/leu.2014.34","article-title":"Racial disparities in the prevalence of monoclonal gammopathies: a population-based study of 12,482 persons from the National Health and Nutritional Examination Survey","volume":"28","author":"Landgren","year":"2014","journal-title":"Leukemia"},{"issue":"2","key":"2025011616302733800_bib7","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1038\/s41591-022-02183-6","article-title":"Prevalence of smoldering multiple myeloma based on nationwide screening","volume":"29","author":"Thorsteinsd\u00f3ttir","year":"2023","journal-title":"Nat Med"},{"issue":"5","key":"2025011616302733800_bib8","doi-asserted-by":"crossref","first-page":"e340","DOI":"10.1016\/S2352-3026(22)00069-2","article-title":"Prevalence of monoclonal gammopathies and clinical outcomes in a high-risk US population screened by mass spectrometry: a multicentre cohort study","volume":"9","author":"El-Khoury","year":"2022","journal-title":"Lancet Haematol"},{"key":"2025011616302733800_bib9","author":"Wilson","year":"1968"},{"issue":"5","key":"2025011616302733800_bib10","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1056\/NEJMoa1300439","article-title":"Lenalidomide plus dexamethasone for high-risk smoldering multiple myeloma","volume":"369","author":"Mateos","year":"2013","journal-title":"N\u00a0Engl J Med"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/145\/3\/253\/2351580\/blood_bld-2024-027065-c-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/145\/3\/253\/2351580\/blood_bld-2024-027065-c-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,16]],"date-time":"2025-01-16T16:30:35Z","timestamp":1737045035000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/145\/3\/253\/534958\/Is-it-time-to-screen-for-multiple-myeloma"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,16]]},"references-count":10,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,1,16]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2024027065","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,16]]}}}